Free Trial
NASDAQ:NERV

Minerva Neurosciences Q2 2025 Earnings Report

Minerva Neurosciences logo
$2.31 -0.09 (-3.75%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$2.38 +0.06 (+2.81%)
As of 09/4/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.95
Beat/Miss
Beat by +$0.52
One Year Ago EPS
N/A

Minerva Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Minerva Neurosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Minerva Neurosciences' Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Minerva Neurosciences Earnings Headlines

Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
See More Minerva Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email.

About Minerva Neurosciences

Minerva Neurosciences (NASDAQ:NERV)., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

View Minerva Neurosciences Profile

More Earnings Resources from MarketBeat